Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 26, Number 6—June 2020

Research

Increased Risk for Carbapenem-Resistant Enterobacteriaceae Colonization in Intensive Care Units after Hospitalization in Emergency Department

Matias Chiarastelli SalomãoComments to Author , Maristela Pinheiro Freire, Icaro Boszczowski, Sueli F. Raymundo, Ana Rubia Guedes, and Anna S. Levin
Author affiliations: Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Main Article

Table 1

Characteristics of patients, bivariate analysis, and conditional logistic regression of variables potentially associated with colonization by carbapenem-resistant Enterobacteriaceae at ICU admission, Hospital das Clínicas, São Paulo, Brazil, September 2015–July 2017*

Covariate Bivariate analysis
 Conditional logistic regression
Cases Controls OR (95% CI) p value OR (95% CI) p value
Female sex 34/103 (33) 91/201 (45) 0.58 (0.35–0.95) 0.03
Mean age, y (range)
 50.55 (14–84)
 49.78 (4–89)
 1.00 (0.99–1.01)
 0.62
Previous hospitalization at ICU admission
Previous stay in another unit during hospitalization 75/101 (74) 163/201 (81) 0.84 (0.44–1.60) 0.60
Previous stay in the ED during hospitalization 62/103 (60) 125/201 (62) 1.07 (0.65–0.77) 0.78
Length of ED stay, d 2 (0–55) 1 (0–37) 1.08 (1.01–1.15) 0.02 1.10 (1.02–1.19) 0.01
ED stay >2 d 34/103 (33) 35/201 (17) 2.45 (1.40–4.32) 0.002
Days of hospitalization before surveillance culture, median (range) 3 (1–95) 2 (1–37) 0.99 (0.99–0.99) <0.001
Transfer from another hospital 43/101 (43) 51/193 (26) 2.79 (1.26–3.68) 0.005 2.52 (1.07–5.89) 0.03
Previous hospitalization
 52/85 (61)
 63/163 (38)
 2.91 (1.53–5.52)
 0.001
Clinical characteristics at ICU admission
Infection 63/101 (63) 82/140 (42) 2.62 (1.52–4.54) 0.001 1.76 (0.56–5.50) 0.33
Sepsis 46/62 (74) 54/81 (66) 1.41 (0.52–3.85) 0.50
Surgery before ICU admission 53/102 (52) 106/194 (55) 0.92 (0.53–1.62) 0.78
Trauma 8/100 (8) 25/194 (13) 0.62 (0.28–1.40) 0.25
Stroke
 5/100 (5)
 17/194 (9)
 0.61 (0.17–2.18)
 0.45
Severity scores
SAPS 3, % median (range) 22 (4–92) 16 (0–98) 1.01 (1.002–1.02) 0.01 1.01 (1.002–1.03) 0.02
SOFA, median (range)
 5 (0–19)
 5 (0–19)
 1.09 (0.95–1.07)
 0.77
Invasive procedures and devices
Dialysis 14/100 (14) 11/194 (6) 2.50 (0.97–6.42) 0.06
Tracheostomy 2/99 (2) 1/194 (0) 4.92 (0.36–44.67) 0.26
Colostomy 2/99 (2) 2/194 (1) 2.00 (0.28–14.34) 0.49
Upper digestive endoscopy 10/101 (10) 5/194 (3) 3.70 (1.11–12.32) 0.003 18.9 (1.83–195.98) 0.01
Colonoscopy 2/101 (2) 0/194 (0)
Parenteral nutrition
 2/101 (2)
 1/ 194 (1)
 3.77 (0.19–74.94)
 0.38
Underlying conditions
CCI score, mean (range) 3.10 (0–9) 2.98 (0–11) 0.99 (0.96–1.02) 0.48
Smoking 25/62 (40) 46/137 (34) 1.17 (0.49–2.78) 0.72
Diabetes mellitus 20/102 (20) 44/198 (22) 0.86 (0.46–1.62) 0.65
Malignant neoplasm 9/102 (9) 23/198 (12) 0.77 (0.35–1.70) 0.52
Rheumatologic or autoimmune disease 11/102 (11) 16/198 (8) 1.44 (0.66–3.15) 0.36
Cirrhosis 15/102 (15) 11/198 (5) 2.25 (0.85–5.91) 0.10
Chronic kidney disease 12/102 (12) 14/198 (7) 1.51 (0.56–3.99) 0.40
Solid organ transplant 8/102 (8) 16/198 (8) 0.62 (0.23–1.64) 0.33
HIV infection 3/100 (3) 7/198 (4) 1.13 (0.27–4.76) 0.86
Hematological malignancy 2/102 (2) 6/198 (3) 0.59 (0.13–2.87) 0.52
Hematopoietic stem cell transplant
 1/102 (1)
 1/198 (0)
 2.00 (0.12–32.42)
 0.63
Antimicrobial drug use
Any drug at ICU admission† 81/99 (81) 142/193 (71) 1.56 (0.83–2.91) 0.161
Carbapenem at ICU admission† 25/80 (31) 12/141 (9) 3.92 (1.51–10.21) 0.005 4.62 (1.30–16.40) 0.02
Any drug use in previous 3 mo 50/72 (69) 48/145 (33) 5.38 (2.31–12.53) <0.001

*Values are no. (%) except as indicated. CCI, Charlson Comorbidity Index; ED, emergency department; GCS, Glasgow Coma Scale; ICU, intensive care unit; OR, odds ratio; SAPS 3, Simplified Acute Physiology 3, presented as prediction of mortality risk in percentage; SOFA, Sequential Organ Failure Assessment.
†Initiated >48 h before ICU admission.

Main Article

Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external